How Molar Charge of the Chiral Auxiliary Shapes Tablet-Directed API Manufacture?

The molar charge of CAS 90719-32-7 in an Evans alkylation sequence is a stereochemical control parameter rather than a formulation variable. In cGMP production of a chiral API intended for direct compression tablets, the oxazolidinone is deprotonated and acylated at a molar ratio of 1.0–1.1 mol auxiliary per 1.0 mol acylating agent; where the acylating agent is moisture-sensitive, the charge is reversed to 1.05–1.15 mol acid chloride per 1.0 mol auxiliary to ensure complete N-acylation. Deprotonation uses 1.0–1.1 molar equivalents of n-butyllithium or lithium bis(trimethylsilyl)amide in THF at −78 °C; the resulting enolate is then alkylated with 1.2–1.8 equivalents of the required electrophile. Batch release at this stage requires diastereomeric excess ≥98% by chiral HPLC on an immobilised polysaccharide column. Temperature excursions above −65 °C during enolate formation are a known batch failure mode in unjacketed pilot reactors; production-scale glass-lined reactors with liquid nitrogen jackets are therefore specified with a control width of ±3 °C around setpoint. Residual solvents are controlled under ICH Q3C(R8), with THF limited to 720 ppm and dichloromethane, if used in workup, limited to 600 ppm. Process controls are documented under ICH Q7 production operations and 21 CFR 211.110. The alkylated auxiliary is cleaved with lithium hydroxide and hydrogen peroxide in THF-water at 0–20 °C, and the isolated chiral acid is converted to a crystalline hydrochloride or sodium salt. After milling to a D90 of 20–80 µm, the API is blended with microcrystalline cellulose, crospovidone, and magnesium stearate and compressed on a rotary tablet press at 8–20 kN main compression force. Terminal products are immediate-release tablets in the 5–200 mg dose range, released under USP <905> content uniformity and USP <711> dissolution.

Product changeover on a dosator capsule filling line using an API derived from this chiral auxiliary route begins with particle-size and flow verification, not with compression force adjustments. The milled API is passed through a conical mill fitted with a 0.8 mm screen and pre-blended with lactose monohydrate in a bin blender at 10–25 rpm for 15–30 minutes. Croscarmellose sodium is added as disintegrant, and magnesium stearate is applied at 0.5–1.0% w/w for a final lubrication step of 3–5 minutes. In the finished capsule fill, the API content is 5–25% w/w for mid-potency products, with total fill weight 250–500 mg for size 0 or size 1 hard gelatin or HPMC capsules. Upstream, the chiral auxiliary is charged at 1.0–1.2 mol per 1.0 mol of substrate during N-acylation; it is absent from the final capsule blend after cleavage and recrystallisation. Encapsulation on dosator or tamping-pin machines at 30,000–70,000 capsules per hour requires a Carr index below 20% and powder bulk density between 0.55 g/cm³ and 0.75 g/cm³. In-line checkweighers reject capsules outside ±3% of target fill weight; segregation failures are typically detected by weight-variation drift exceeding ±3% and by content-uniformity acceptance values approaching 15.0. Release testing includes USP <905>, USP <711> dissolution at 75 rpm in 900 mL of specified media, and 21 CFR 211.165 finished-product testing. Terminal product types are immediate-release hard gelatin and HPMC capsules in unit-dose or bulk configurations.

Lyophilised Injectable API Crystallisation After Auxiliary Removal

Sterile filtration of a parenteral API synthesised through the oxazolidinone route requires that every chiral auxiliary fragment be accounted for before the bulk solution reaches the filter membrane. Crude chiral acid obtained after lithium hydroxide–hydrogen peroxide cleavage is recrystallised from a Class 3 solvent system such as ethanol/water or acetone/water until residual oxazolidinone is ≤0.10% w/w, the identification threshold in ICH Q3A(R2). The auxiliary charge ratio during synthesis remains 1.05–1.20 mol per 1.00 mol of substrate; unreacted auxiliary is removed in workup rather than carried into the injectable formulation. The purified API is dissolved in Water for Injection at 10–50 mg/mL, pH-adjusted with dilute hydrochloric acid or sodium hydroxide, and passed through a 0.2 µm sterilising-grade polyethersulfone or PVDF membrane in an ISO 14644-1:2015 Class 5 area. Pre-filtration bubble point and product-specific adsorption testing are required because polyethersulfone membranes can adsorb low-concentration API at 1–10 mg/mL. Lyophilisation proceeds with a shelf ramp from −40 °C to −20 °C during primary drying at chamber pressure 80–120 mTorr (10.7–16.0 Pa), followed by secondary drying at 25–35 °C for 6–12 hours. Parenteral operations follow EU GMP Annex 1 aseptic processing requirements. Release testing applies USP <788> particulate matter, USP <790> visible particulate inspection, USP <85> bacterial endotoxins, and ICH Q3D elemental impurities. Terminal products include sterile lyophilised powders in 5 mL or 10 mL vials intended for reconstitution, and ready-to-use sterile solutions in ampoules or pre-filled syringes where the API salt demonstrates adequate solution stability.

Granulation endpoint control for low-dose oral sachets prepared from the derived API is determined by wet-mass consistency, not by compression behaviour. In a high-shear granulation suite, the milled API is charged at 1–10% w/w of the dry granulate, povidone K30 binder solution is added at 2–5% w/w solids, and lactose monohydrate or mannitol serves as the filler. The chiral intermediate itself is not present in the granulation; its upstream molar charge is 1.0–1.2 mol per 1.0 mol of substrate, and residual solvents are limited by ICH Q3C(R8). Wet massing occurs in a vertical high-shear granulator at impeller tip speed 5–10 m/s and chopper speed 1,000–3,000 rpm for 3–8 minutes. The wet mass is screened through a 1.5–2.0 mm sieve and dried in a top-spray fluid-bed dryer at inlet air temperature 60–70 °C until loss on drying is ≤2.0% w/w. Over-granulation, evidenced by wet-mass density above 1.2 g/cm³, can produce granules with retained moisture pockets that fail USP <711> dissolution at 30 minutes. Dried granules are sieved through a 1.0 mm screen and filled on stick-pack or sachet form-fill-seal lines at 30–60 packs per minute. Release testing includes Ph. Eur. 2.9.3 preparation for dissolution, USP <711> dissolution with Q=80% at 30 minutes, and 21 CFR 211.110 in-process blend uniformity. Terminal product types are single-dose oral granules for solution or suspension, paediatric or geriatric dose fractions, and multi-dose bulk granules for extemporaneous reconstitution.

When Extended-Release Matrix Tablets Demand Polymer Hydration Control

Extended-release development for an API obtained after chiral auxiliary cleavage introduces polymer hydration fronts that are independent of the stereochemical route upstream. The auxiliary is consumed at a molar charge of 1.05–1.15 mol per 1.00 mol of acyl substrate, and the isolated API must meet a residual oxazolidinone limit of ≤0.10% w/w under ICH Q3A(R2) before formulation. In the matrix blend, hypromellose type 2208 K100M is included at 20–35% w/w, the API at 10–30% w/w, microcrystalline cellulose as diluent, colloidal silicon dioxide as glidant, and magnesium stearate as lubricant. Direct compression on a rotary tablet press applies pre-compression 4–8 kN and main compression 15–25 kN, targeting tablet hardness 100–180 N and friability ≤1.0% by Ph. Eur. 2.9.7 or USP <1216>. The dissolution profile is measured by USP <711> Apparatus II at 50 rpm in 900 mL of media, with sampling at 1, 2, 4, 8, 12, and 24 hours in a pH-shift protocol from 0.1 N HCl to pH 6.8 phosphate buffer. Matrix tablets that crack along the hydration front during the pH transition can produce non-Fickian release; development batches must therefore monitor gel-layer thickness and polymer grade for the specific salt form. Published data for this specific auxiliary-derived API in fixed-dose extended-release matrices may be limited. Terminal products include 12-hour and 24-hour extended-release tablets, bilayer configurations combining an immediate-release loading dose and a matrix core, and osmotic pump variants where laser-drilled orifices replace polymer hydration for poorly soluble API forms.

Where an oral solution is required for dysphagia, dose titration, or paediatric use, the derived API must first satisfy pH-solubility and photostability screening in buffered vehicles. The upstream auxiliary molar charge is 1.05–1.15 mol per 1.00 mol of substrate, and the final solution must be free of residual oxazolidinone above the ICH Q3A(R2) identification threshold of 0.10% w/w. In a typical manufacturing batch, the API is dissolved at 1–20 mg/mL in purified water containing propylene glycol 10–30% v/v and sorbitol 20–40% w/v; sodium benzoate or potassium sorbate is included at 0.1–0.2% w/w in preserved multi-dose products. The solution is prepared in a jacketed stainless-steel vessel at 20–25 °C with high-torque agitation, pH-adjusted with dilute hydrochloric acid or sodium hydroxide, and clarified through a 10 µm polish filter before filling into amber PET bottles or unit-dose cups. Photostability screening follows ICH Q1B when clear unit-dose cups are used; amber packaging reduces UV exposure. In-process controls include pH, density, and clarity, with release testing under 21 CFR 211.165 and stability evaluated per 21 CFR 211.166. Residual solvent compliance follows ICH Q3C(R8), and elemental impurities are controlled under ICH Q3D. Terminal product types include oral drops, syrups, and unit-dose oral solution cups for single-administration use.